Welcome to our dedicated page for I-Mab news (Ticker: IMAB), a resource for investors and traders seeking the latest updates and insights on I-Mab stock.
I-Mab (NASDAQ: IMAB) is a clinical-stage biopharmaceutical company pioneering novel immunotherapies for cancer and autoimmune diseases. This page provides investors and industry professionals with timely updates on the company’s clinical trials, strategic partnerships, and operational developments.
Access consolidated news about IMAB’s innovative pipeline, including therapies targeting CD73 (uliledlimab) and Claudin 18.2 (givastomig). Stay informed on milestones across all development phases, from preclinical research to late-stage trials, with verified updates on regulatory progress and collaborative agreements.
Key content includes earnings reports, clinical data disclosures, licensing deals, and management commentary. All materials are sourced directly from company filings and official communications to ensure accuracy.
Bookmark this page for streamlined tracking of IMAB’s advancements in immuno-oncology and autoimmune research. Regular updates provide critical insights into the company’s progress in addressing unmet medical needs through differentiated biologics.
I-Mab (NASDAQ: IMAB) presented positive Phase 1b dose escalation data for givastomig in combination with nivolumab and mFOLFOX6 at ESMO GI 2025. The study evaluated first-line therapy in Claudin 18.2-positive gastric cancer patients.
Key highlights include a confirmed objective response rate (ORR) of 83% (10/12) at selected doses (8 mg/kg and 12 mg/kg) for the ongoing expansion study. The trial demonstrated efficacy across PD-L1 and CLDN18.2 expression levels, with responses in low-expression tumors. With a median follow-up of 9.0 months, the treatment showed favorable tolerability with minimal Grade 3 adverse events.
The study enrolled 17 U.S. patients across three dose levels (5, 8, and 12 mg/kg), achieving a 71% ORR across all doses and a 100% disease control rate. The longest treatment duration was 13.3 months, with 8 patients remaining on treatment at data cutoff.
I-Mab (NASDAQ: IMAB) announced the publication of promising clinical data for givastomig, their bispecific Claudin 18.2 x 4-1BB antibody, in Clinical Cancer Research. The Phase 1 monotherapy study demonstrated an objective response rate (ORR) of 18% in heavily pretreated Claudin 18.2-positive gastric cancer patients.
Key findings from the 75-patient study include:
- 7 confirmed partial responses in 43 evaluable patients with CLDN18.2-positive advanced gastric cancer
- Disease control rate (DCR) of 49% (21/43 patients)
- Median duration of response of 9.4 months
- Activity observed across Claudin 18.2 expression levels (11% to 100%)
- No dose-limiting toxicity reported up to 15 mg/kg Q2W and 18 mg/kg Q3W
The company will present additional combination therapy data with nivolumab plus mFOLFOX6 at the upcoming ESMO GI Cancers Congress 2025 on July 2nd in Barcelona.
I-Mab (NASDAQ: IMAB) announced positive Phase 1b dose escalation data for givastomig in combination with immunochemotherapy for first-line gastric cancer treatment. The study demonstrated an impressive 71% objective response rate (ORR) across all dose levels, with an even higher 83% ORR in the selected dose expansion cohorts (8 and 12 mg/kg).
Key highlights include rapid and deepening responses even in tumors with low PD-L1 and CLDN18.2 expression, with a 100% disease control rate across all three dose levels. The treatment showed a favorable safety profile with mostly Grade 1 or 2 adverse events. The study enrolled 17 treatment-naïve metastatic gastric cancer patients in the U.S., with 8 patients still continuing treatment, the longest duration being 11.3 months.
I-Mab (NASDAQ: IMAB), a U.S.-based global biotech company specializing in precision immuno-oncology agents, has announced its participation in the Jefferies Global Healthcare Conference scheduled for June 3-5, 2025. The company's management will engage in a fireside chat and one-on-one meetings on June 5 at 3:45 PM ET.
Additionally, I-Mab revealed that new data regarding their lead program, givastomig, has been accepted for a Mini Oral presentation at the ESMO GI Cancers Congress 2025, taking place on July 2, 2025, in Barcelona, Spain.
I-Mab, a U.S.-based global biotech company, announced that their givastomig combination study abstract has been selected for a mini-oral presentation at the ESMO Gastrointestinal Cancers Congress 2025.
The study focuses on combining givastomig with nivolumab and chemotherapy for cancer treatment. The congress will take place from July 2-5 in Barcelona, Spain. Chief Medical Officer Dr. Phillip Dennis expressed enthusiasm about the acceptance of their clinical data for presentation.
The company, which specializes in developing precision immuno-oncology agents, will provide additional details about the presentation as more information becomes available from the conference.
I-Mab (NASDAQ: IMAB) reported its full year 2024 financial results, highlighting progress in its givastomig Phase 1b combination trial for first-line gastric cancer. The company completed enrollment ahead of schedule in the first expansion cohort, with topline dose escalation data expected in 2H 2025.
Financial highlights include a strong cash position of $173.4 million as of December 31, 2024, providing runway into 2027. The company reported a net loss of $22.2 million for 2024, compared to $207.7 million in 2023. R&D expenses were $21.8 million, while administrative expenses reached $29.7 million.
Key developments include the completion of Greater China assets divestiture and business operations restructuring. The company is focusing on advancing givastomig, a CLDN18.2 x 4-1BB bispecific antibody, with Phase 1b dose expansion study results expected in 1H 2026.
FAQ
What is the current stock price of I-Mab (IMAB)?
What is the market cap of I-Mab (IMAB)?
